SEARCH

SEARCH BY CITATION

References

  • 1
    Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem 1999;274:1372932.
  • 2
    Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79:95863.
  • 3
    Francis SH, Lincoln TM, Corbin JD. Characterization of a novel cGMP binding protein from rat lung. JBiolChem 1980;255:6206.
  • 4
    Lincoln TM, Hall CL, Park CR, Corbin JD. Guanosine 3′:5′-cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci USA 1976;73:255963.
  • 5
    Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:4539.
  • 6
    Doh H, Shin CY, Son M, Ko JL, Yoo M, Kim SH, Kim WB. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharmacol Res 2002;25:8738.
  • 7
    Sweetnam P, Campbell S, Grogan M, Kirk B, McGonigle S, Paradise E, Goldstein I. SL-x 2101, a novel long acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: In vivo and in vitro studies. J Sex Med 2006;3(1 suppl) Abstract 51.
  • 8
    Kotera J, Fujishige K, Michibata H, Yuasa K, Kubo A, Nakamura Y, Omori K, Biochem Pharmacol. Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Pharmacol 2000;60:133341.
  • 9
    Lee J, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism and excretion of 5-ethyl-2{5-4-(2-hydroxyethyl) piperazine-1-sulfonyl-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo3,2-d-pyrimidin-4-one (SK 3530) in rats. Rapid Commun Mass spectrom 2007;2007:113949.
  • 10
    Francis SH, Corbin JD, Bischoff E. cGMP: Generators and therapeutic Implications From Handbook of Experimental Pharmacology, Vol. 191. New York: Springer Verlag; 2009:367408.
  • 11
    Francis SH, Corbin JD. Molecular Mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003;4:45765.
  • 12
    Weeks JL, II, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005;17:59.
  • 13
    Salem EA, Kendrici M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006;7:6619.
  • 14
    Kim B, Lim H, Chung J, Kim J, Lim KS, Sohn D, Cho J, Yu S, Shin S, Paick J, Jang I. Safety, tolerability, and phamacokinetics of udenafil, a novel PDE-5 inhibitor in healthy young korean subjects. BJCP 2008;65:84854.
  • 15
    Prince W, Campbell AS, Tong W, Sweetnam P, Willett M, Roesch BG, Garcia WD, Rosen RC, Goldstein I. SLx-2102, a new long-acting PDE5 inhibitor: Preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol 2006;175:924.
  • 16
    Peterson C, Sweringen D. Pharmacokinetics of Avanafil, a new PDE5 Inhibitor being developed for treating erectile dysfunction. J Sex Med 2006;3(1 suppl):Abstract 122.
  • 17
    Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:267280.
  • 18
    Glina S, Toscano I, Gomatzky C, De Goes PM, Junior AN, Claro JF, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: A phase II clinical trial. J Sex Med 2009;6:5537.
  • 19
    Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology 2003;62:1215. discussion 125–6.
  • 20
    Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W. Wicker P for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397404.
  • 21
    Padma-Nathan H. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients. Int J Clin Prac 1998;52:15.
  • 22
    Dinsmore W, Hodges M, Hargreaves C, Osterloh I, Smith M, Rosen R. Sildenafil citrate (Viagra) in erectile dysfunction: Near normalization in men with broad-spectrum erectile dysfunction compared with age-matched, healthy control subjects. Urology Apr 1999;53:8005.
  • 23
    Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology May 1999;53:10118.
  • 24
    Tan HM, Moh CLC, Mendoza JB, Gana T Jr, Albano GJ, De La Cruz R, Chye PLH, Sam CCW. ASSESS-1 Study Group. Asian sildenafil efficacy and safety study (ASSESS-1): A double-blind, placebo-controlled flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000;56:63540.
  • 25
    Christiansen E, Guirguis WR, Cox D, Osterloh IH for the Sildenafil Multicenter Study Group. Long-term efficacy and safety of oral VIAGRA (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000;12:17782.
  • 26
    Olsson AM, Speakman MJ, Dinsmore WW, Giuliano F, Gingell C, Maytom M, Smith MD, Osterloh I. Sildenafil citrate (VIAGRA) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract Nov 2000;54:5616.
  • 27
    Meuleman E14Cuzin B, Opsomer RJ, Hartmann U, Bailey MJ, Maytom MC, Smith MD, Osterloh IH. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2001;87:7581.
  • 28
    Chen KK, Hsieh JT, Huang ST, Jiaan DBP, Lin JSN, Wang CJ, for the Assess 3 Study Group. ASSESS-3: A randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001;13:2219.
  • 29
    Giuliano F, Pena BM, Mishra A, Smith MD. Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction. Qual Life Res 2001;10:35969.
  • 30
    Lewis R, Bennett CJ, Borkon WD, Boykin WH, Althof SE, Stecher VJ, Siegel RL. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction inventory of treatment satisfaction, questionnaire. Urology 2001;57:9605.
  • 31
    Becher E. A Tejada Noriega, R Gomez and R Decia, Sildenafil citrate in the treatment of men with erectile dysfunction in southern Latin America: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res 2002;14(2 suppl):S3341.
  • 32
    Glina S, Bertero E, Claro J, Damia R, Faria G, Fregonesi A, Jaspersen J, Mendoza A, Jr, LC Rocha D Mattos, Sotomayor M, Teloken C, Ureta S, Zonana E, Ugarte F. Efficacy and safety of flexible-dose oral sildenafil citrate in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res 2002;14(2 suppl):S2732.
  • 33
    Gomez F, Davila H, Costa A, Acuna A, Wadskier LA, Plua P. Efficacy and safety of oral sildenafil citrate in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: A double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002;14(2 suppl):S427.
  • 34
    Levinson IP, Khalaf IM, Shaeer KZM, Smart DO. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men in Egypt and South Africa. IJIR 2003;15(1 suppl):S259.
  • 35
    O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S, The United States Self-Esteem and Relationship Questionnaire Study Group. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: A multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol 2006;175:105862.
  • 36
    Althof SE, O'leary MP, Cappelleri JC, Hvidsten K, Stecher VJ, Glina S, King R, Siegel RL, International SEAR Study Group. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006;3:5219.
  • 37
    Heiman JR, Talley DR, Bailen JL, Oskin TA, Rosenberg SJ, Pace CR, Creanga DL, Bavendam T. Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: A multicentre, randomised, double-blind, placebo-controlled trial. BJOG 2007;114:43747.
  • 38
    Buranakitjaroen P, Mangklabruks A, Leungwattanakij S, Ngaothamatasn W, Malhotra C, Chee C, Mohamed SR, Dato'Johan RM. Thai-Malaysian-Singapore Erectile Dysfunction Study Group (THAMES Group). Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. J Med Assoc Thai 2007;90:11008.
  • 39
    Seftel AD, Creanga DL, Levinson IP. Sildenafil reduces bother associated with erectile dysfunction: Pooled analysis of five randomized, double-blind trials. Int J Impot Res 2007;19:58490.
  • 40
    Hundertmark J, Esterman A, Ben-Tovim D, Austin MA, Dougherty M. The South Australian couples sildenafil study: Double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. J Sex Med 2007;4:112635.
  • 41
    Kadioglu A, Grohmann W, Depko A, Levinson IP, Sun F, Collins S. Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: Multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. J Sex Med 2008;5:72634.
  • 42
    Zonana Farca E, Francolugo-Vélez V, Moy-Eransus C, Orozco Bravo A, Tseng LJ, Stecher VJ. Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: A randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res 2008;20:4028.
  • 43
    Jones LA, Klimberg IW, McMurray JG, Padula R, Tseng LJ, Stecher VJ. Effect of sildenafil citrate on the male sexual experience assessed with the Sexual Experience Questionnaire: A multicenter, double-blind, placebo-controlled trial with open-label extension. J Sex Med 2008;5:195564.
  • 44
    Rendell M, Rajfer J, Wicker P, Smith M, Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized control trial. JAMA 1999;281:4216.
  • 45
    Boulton AJM, Selam JL, Sweeney M, Ziegler D. Sildenafil for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44:1296301.
  • 46
    Stuckey BGA, Jadzinskey MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, Manzano P, Deerochanawong C. Sildenafil citrate for treatment of erectile dysfunction in men with Type 1 diabetes. Diabetes Care 2003;20:27984.
  • 47
    Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: A randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18:20510.
  • 48
    Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: Results of a placebo-controlled trial with sildenafil citrate. Am J Psych 2001;158:162330.
  • 49
    Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: A randomized controlled trial. JAMA 2003;289:5664.
  • 50
    Tignol J, Furlan PM, Gomez-Beneyto M, Opsomer R, Schreiber W, Sweeney M, Wohlhuter C. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol 2004;19:1919.
  • 51
    Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, Stecher VJ. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2006;67:2406.
  • 52
    Giuliano F, Hultling C, El Masry WS, Smith M, Osterloh I, Orr M, Maytom M, for the Sildenafil Study Group. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 1999;46:1521.
  • 53
    Hultling C, Giuliano F, Quirk F, Pena B, Mishra A, Smith D. Quality of life in patients with spinal cord injury receiving VIAGRA (sildenafil citrate) for the treatment of erectile dysfunction. Spinal Cord 2000;38:36370.
  • 54
    Fowler CJ, Miller JR, Sharief MK, Hussain IF, Stecher VJ, Sweeney M. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:7005.
  • 55
    Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: A double-blind, placebo controlled, randomized study. J Urol 2009;181:2528.
  • 56
    Olsson AM, Persson C-A. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Prac 2001;55:1716.
  • 57
    DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:14753.15
  • 58
    Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: A prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004;164:51420.
  • 59
    Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005;95:3642.
  • 60
    Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, Mancia G. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: A randomized controlled trial. Am J Hypertens 2004;17:113542.
  • 61
    McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: A randomised double-blind trial with open-label extension. Int J Clin Pract 2007;61:18439.
  • 62
    Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:6974.
  • 63
    Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(2B suppl):6790.
  • 64
    Christiansen E, Guirguis WR, Cox D. Osterloh IH for the Sildenafil Multicenter Study Group. Long-term efficacy and safety of oral VIAGRA (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000;12:17782.
  • 65
    Laties AM, Fraunfelder FT. Ocular safety of Viagra® (sildenafil citrate). Tr Am Ophth Soc 1999;XCVII:11528.
  • 66
    Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3:1227.
  • 67
    Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: A review of the evidence to date. Drug Safety 2009;32:118.
  • 68
    Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C44C.
  • 69
    Jackson G, Sweeney M, Osterloh IH. Sildenafil citrate (Viagra®): A cardiovascular overview. [Review]. Br J Cardiol 1999;6:32534.
  • 70
    Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. NEJM 2000;342:16226.
  • 71
    Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial.see comment. JAMA 2002;287:71925.
  • 72
    Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003;57:597600.
  • 73
    Fox KM, Thadani U, Ma PTS, Nash SD, Keating Z, Czorniak MA, Gillies H, Keltai M. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003;24:2006212.
  • 74
    Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): An updated perspective. Urology 2006;68(3 suppl):4760.
  • 75
    Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC. IC351. On Demand Dosing Study Group. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:29.
  • 76
    Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology 2003;62:1215.
  • 77
    Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, Hsieh JT, Su CK, Costigan TM, and Emmick JT. Efficacy and Safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction: A randomized, double blind, parallel, placebo controlled clinical study. J Sex Med 2004;1:2018.
  • 78
    Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004;94:8717.
  • 79
    Skoumal R, Chen J, Kula K, Breza J, Calomfiresca N, Basson B, Kopernicky V. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:3629.
  • 80
    Seftel AD, Wilson SK, Knapp PM, Shin J, Wang WC Ahuya S. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol 2004;172:6527.
  • 81
    McMahon CG, Stuckey BGA, Lording GA, Wittert GA, Murpy A, Shin J, Sutherlant PD, Palmer NR, Lowy MP, Jesudason DR, Fredlund P. A6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: A randomized, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract 2005;59:1439.
  • 82
    Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker S, Beasley CM. Efficacy and safety of oral tadalafil in the treatment of men with erectile dysfunction: A randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005;2:68598.
  • 83
    Young JM, Feldman RA, Auerback SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM Jr, Hague JA, Ahuja S. Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial. J Androl 2005;26:3108.
  • 84
    Guo YL, Zhu JC, Pan TM, Ding Q, Wang YX, Cheong NF, Lim E, Shen W, Chan M, Venugopalan M. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006;13:7217.
  • 85
    Nagao K, Kimoto Y, Marumo K, Tsujimura A, Vail G, Watts S, Ishil N, Kamidono S. The efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006;68:84551.
  • 86
    McMahon CG, Carson CC, Fischer CJ, Wang WC, Florio VA, Bradley JD. Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. J Sex Med 2006;3:50411.
  • 87
    Saylan M, Khalaf I, Kadioglu A, Zaki Shoair K, Beheiry A, Wang WC, Kopernicky V, Esen A. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. Int J Clin Prac 2006;60:8129.
  • 88
    Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, Wang WC, Kopernicky V. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: A randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl 2006;8:68592.
  • 89
    Porst H, Giuliano FA, Glina S, Ralph D, Casabe AR, Mboussa AE, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment erectile dysfunction: Results of a multicenter randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:3519.
  • 90
    Rajfer J, Aliotta PJ, Steidle CP, Fitch WP, III, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-bind, placebo-controlled study in the United States. Int J Impot Res 2007;19:95103.
  • 91
    Saenz de Tejada 1, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:215964.
  • 92
    Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock G, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetes Med 2008;25:13846.
  • 93
    Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. J Urol 2004;172:103641.
  • 94
    Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006;66:43944.
  • 95
    Giuliano F, Sanchez-Ramos A, Lochner-Ernst D, Del Popolo G, Cruz N, Leriche A, Lombardi G, Reichert S, Dahl P, Elion-Mboussa A, Casariego J. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. Arch Neurol 2007;64:158492.
  • 96
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:14017.
  • 97
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:122834.
  • 98
    Hellstrom WJ, Overstreet JW, Yu A, Saikali K, Shen W, Beasley CM Jr, Watkins VS. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:88791.
  • 99
    Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:185560.
  • 100
    Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004;1:1617.
  • 101
    Patterson D, Kloner R, Effron M, Emmick J, Bedding A, Warner M, Mitchell M, Braat S, MacDonald T. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005;60:45968.
  • 102
    Weinsaft JW, Hickey K, Bokhari S, Shahzad A, Bedding A, Costigan TM, Warner MR, Emmick JT, Bergmann SR. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coron Artery Dis 2006;17:4939.
  • 103
    Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, Watts S Mitchell CL, McGill JM. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: Results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53:105865.
  • 104
    Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:21609.
  • 105
    Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:1929.
  • 106
    Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:76371.
  • 107
    Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol 2004;45:63441. discussion 41.
  • 108
    Nagao K, Ishii N, Kamidono S, Osada T. Safety and efficacy of vardenafil in patients with erectile dysfunction: Result of a bridging study in Japan. Int J Urol 2004;11:51524.
  • 109
    Stief C, Porst H, Saenz De Tejada I, Ulbrich E, Beneke M. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004;58:2309.
  • 110
    Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P et al. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005;2:699708.
  • 111
    Edwards D, Hackett G, Collins O, Curram J. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006;3:102836.
  • 112
    Chen KK, Paick JS, Ishii N. The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. J Sex Med 2007;4:75361.
  • 113
    Martin-Morales A, Meijide F, Garcia N, Artes M, Munoz A. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007;4:4407.
  • 114
    Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007;100:1306.
  • 115
    Tan HM, Chin CM, Chua CB, Gatchalian E, Kongkanand A, Moh CL et al. Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. Asian J Androl 2008;10:495502.
  • 116
    Rosenberg MT, Adams PL, McBride TA, Roberts JN, McCallum SW. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: The ENDURANCE study. Int J Clin Pract 2009;63:2734.
  • 117
    Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:77783.
  • 118
    Ishii N, Nagao K, Fujikawa K, Tachibana T, Iwamoto Y, Kamidono S. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006;13:106672.
  • 119
    Ziegler D, Merfort F, Van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:88391.
  • 120
    Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170:127883.
  • 121
    Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: The depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006;163:7987.
  • 122
    Van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005;2:85664.
  • 123
    Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006;66:2106.
  • 124
    Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008;5:145567.
  • 125
    Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P et al. Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94:13019.
  • 126
    Bischoff E. Vardenafil preclinical trial data: Potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004;16(1 suppl):S347.
  • 127
    Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:200612.
  • 128
    Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008;5:94653.
  • 129
    Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK, Park KS, Lee SW, Kim SW, Park K, Jung H, Park NC. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: A multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl 2008;10:7918.
  • 130
    Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:267280.
  • 131
    Glina S, Toscano I, Gomatzky C, De Goes PM, Junior AN, Claro JF, Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: A phase II clinical trial. J Sex Med 2009;6:5537.
  • 132
    Chen JK, Chan SH, Chang LS, Chan JY. Participation of paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J Urol 1997;158:23844.
  • 133
    Rampin O, Jerome N, Suaudeau C. Proerectile effects of apomorphine in mice. Life Sci 2003;72:232936.
  • 134
    Chen JK, Chan JY, Chang LS. Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J Urol 1999;162:23742.
  • 135
    Brien SE, Smallegange B, Gofton WT, Heaton JPW, Adams MA. Development of a rat model of sexual performance anxiety: Effect of behavioural and pharmacological hyperadrenergic stimulation on APO-induced erections. Int J Impot Res 2002;14:10715.
  • 136
    Dula E, Keating W, Siami PF, Edmonds A, O'neil J, Buttler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000;56:1305.
  • 137
    Von Keitz AT, Stroberg P, Bukofzer S, Mallard N, Hibberd M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int 2002;89:40915.
  • 138
    Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:5583.
  • 139
    Heaton JP, Dean J, Sleep DJ. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res 2002;14:614.
  • 140
    Heaton JP. Apomorphine: An update of clinical trial results. Int J Impot Res 2000;12(4 suppl):S6773.
  • 141
    Fagan TC, Buttler S, Marbury T, Taylor A, Edmonds A, SL APO Study Group. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001;88:7606.
  • 142
    Adams MA, Perdok RJ, Padley RJ, Sleep DJ. Safety and tolerability of apomorphine SL in men with cardiovascular disorders. Eur Urol 2002;1(suppl):2832.
  • 143
    Ralph DJ, Sleep DJ, Perdok RJ, Padley RJ. Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and III studies. Eur Urol 2002;1(suppl):217.
  • 144
    Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci 2002;99:113816.
  • 145
    Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 1996;58:177784.
  • 146
    Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. J Urol 1998;160:38993.
  • 147
    Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levİne N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000;56:6416.
  • 148
    Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16:519.
  • 149
    Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:519.
  • 150
    Eardley I, Mirone V, Montorsi F et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. Br J Urol Int 2005;96:132332.
  • 151
    Dean J, Hackett GI, Gentile V et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:65061.
  • 152
    Eardley I, Montorsi F, Jackson G et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: Post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007;100:1229.
  • 153
    Eardley I, Wright P, Macdonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:12715.
  • 154
    Porst H, Behre HM, Jungwirth A, Burkart M. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction. An open, randomized cross-over study with flexible dosing. Eur J Med Res 2007;12:617.
  • 155
    Afif-Abdo J, Teloken C, Damião R, Koff W, Wroclawski E, Yamasaki R, Otávio Torres L, Sabaneeff J, Faria G, Carlos Pompeo A, Cortado P, Glina S. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int 2008;102:82934.
  • 156
    Giammusso B, Colpi GM, Cormio L, Ludovico G, Soli M, Ponchietti R, Montorsi F, Panzironi C, Guastella B. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008;81:40915.
  • 157
    Brindley GS. Cavernosal alpha–blockade: A new technique for investigating and treating erectile impotence. Br J Psych 1983;143:3327.
  • 158
    Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
  • 159
    Karim SMM, Adaikan PG. Physiological roles and pharmacological actions of prostaglandin in relation to human reproduction. In: KarimSMM, ed. Prostaglandins and reproduction. Lancaster: MTP Press Ltd; 1975:2375.
  • 160
    Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine monophosphate in prostaglandin El-induced penile erection in rabbits. Eur Urol 1995;28:25965.
  • 161
    Traish AM, Moreland RB, Gallant C, Huang YH, Goldstein I. G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Recept Signal Trans-duct 1997;7:12132.
  • 162
    Moreland RB, Albadawi H, Bratton C, Patton G, Goldstein I, Traish A, Watkins MT. 02-dependent prostanoid synthesis activates functional PGE receptors on corpus cavernosum smooth muscle. Am J Physiol 2001;281:H5528.
  • 163
    Molderings GJ, Van Ahlen H, Gothert M. Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impot Res 1992;4:1925.
  • 164
    Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157:19205.
  • 165
    Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:8737.
  • 166
    Traish A, Gupta S, Gallant C, Huang YH, Goldstein I. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res 1998;10:21523.
  • 167
    Vemulapalli S, Kurowski S. Phentolamine mesylate relaxes rabbit corpus cavernosum by a nonadrenergic, noncholinergic mechanism. Fundam Clin Pharmacol 2001;15:17.
  • 168
    Adaikan PG, Kottegoda SR, Karim S, Ratnam SS. Adrenergic mechanism in penile erection. Asia Pac J Pharmacol 1986;1:1413.
  • 169
    Polak JM, Gu J, Mina S, Bloom SR. Vipergic nerves in the penis. Lancet 1981;2:2179.
  • 170
    Ehmke H, Junemann KP, Mayer B, Kummer W. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation. Int J Impot Res 1995;7:14756.
  • 171
    Hedlund P, Ny L, Alm P, Andersson KE. Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. J Urol 2000;164:86875.
  • 172
    Miller MA, Morgan RI, Thompson CS, Mikhailidis DP, Jeremy JY. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: An in vitro study. Int J Impot Res 1995;7:91100.
  • 173
    Hedlund P, Alm P, Ekstrom P, Fahrenkrug J, Hannibal J, Hedlund H, Larsson B, Andersson KE. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestİnal polypeptide in human corpus cavernosum. Br J Pharmacol 1995;116:225866.
  • 174
    Wagner G, Gerstenberg T. Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in men per se. World J Urol 1987;5:1712.
  • 175
    Dinsmore WW, Gingell C, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: A multicentre double-blind placebo-controlled study. BJU Int 1999;83:2749.
  • 176
    Sandhu D, Curless E, et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Imp Res 1999;11:917.
  • 177
    Adaikan PG, Ratnam SS. Pharmacological consideration of intracavernous drug injection in the treatment of impotence. Acta Urol Belg 1988;56:14953.
  • 178
    Kirkeby HJ, Forman A, Andersson KE. Comparison of the papaverine effects on isolated human penile circumflex veins and corpus cavernosum. Int J Impot Res 1990;2:4954.
  • 179
    Iguchi M, Nakajima T, Hisada T, Sugimoto T, Kurachi Y. On the mechanism of papaverine inhibition of the voltage-dependent Ca++ current in isolated smooth muscle cells from the guinea pig trachea. J Pharmacol Exp Ther 1992;263:194200.
  • 180
    Kim NN, Goldstein I, Moreland RB, Traish AM. Alpha-adrenergic receptor blockade by phentolamine increases the effİcacy of vasodilators in penile corpus cavernosum. Int J Impot Res 2000;12(1 suppl):S2636.
  • 181
    Bechara A, Casabé A, Chéliz G, Romano S, Fredotovich N. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine, and phentolamine in non-responders to high papaverine plus phentolamine doses. J Urol 1996;155:913.
  • 182
    Seyam R, Mohamed K, Akhras AA, Rashwan H. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. Int J Impot Res 2005;17:346.
  • 183
    Padma-Nathan H, Hellstrom W, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N, Cowley C, Nemo KJ, Spivack AP, Stephens DE, Todd LK. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:17.
  • 184
    Hellstrom WJG, Bennett AH, Gesundheit N, Kaiser FE, Lue TF, Padma-Nathan H, Peterson CA, Tam PY, Todd LK, Varady JC, Place VA. Multicenter, double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil in men with chronic erectile dysfunction. Urology 1996;48:851.
  • 185
    Urciuoli R, Cantisani T, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004;2:CD001784.
  • 186
    Porst H. Transurethral alprostadil with MUSE (Medicated Urethral System for Erection) vs. Intra-cavernous alprostadil-a comparative study in 103 patients with Erectile Dysfunction. Int J Impotence Res 1997;9:18792.
  • 187
    Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intercavernous alprostadil alfadex is (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000;55:477.
  • 188
    McVary K, Polepalle S, et al. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol 1999;162(3 Pt 1):72630.
  • 189
    Wolfson B, Pickett S, et al. Intraurethral prostaglandin E-2 cream: A possible alternative treatment for erectile dysfunction. Urology 1993;42:735.
  • 190
    Kim E, McVary K. Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 1995;153:182830.
  • 191
    Goldstein I, Payton T, et al. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001;57:301.
  • 192
    Padma-Nathan H, Yeager J. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in1732 patients. Urology 2006;68:386.